Form 4: Apellis Pharmaceuticals Acquired by Biogen for $41/Share

Apellis Pharmaceuticals has been acquired by Biogen in a transaction valued at $41.00 per share plus contingent value rights.

Summary

• Apellis Pharmaceuticals, Inc. has completed its merger with a subsidiary of Biogen Inc.
• Shareholders received $41.00 per share in cash plus one non-transferable contingent value right (CVR) per share.
• The CVR entitles holders to potential additional payments of up to $4.00 per share upon the achievement of specific milestones.
• All outstanding common stock, restricted stock units (RSUs), and vested stock options with an exercise price below $41.00 were converted into the right to receive the cash consideration and CVRs.
• Stock options with an exercise price of $45.00 or greater were cancelled without consideration.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive outcome for shareholders as it provides immediate liquidity at a set price with additional upside potential via CVRs.

Positives

• Shareholders received a definitive cash payout of $41.00 per share.
• Potential for additional upside of up to $4.00 per share through contingent value rights (CVRs) based on future milestones.

Negatives

• Stock options with exercise prices of $45.00 or higher were cancelled without any payout, resulting in a total loss of value for those specific holdings.
• The company has ceased to be an independent publicly traded entity.

Risks

• The realization of the additional $4.00 per share is contingent upon meeting specific, undisclosed milestones, which may not be achieved.
• The CVRs are non-transferable, limiting liquidity for shareholders regarding the potential future payout.

Future Outlook

The company has been acquired by Biogen and is now a wholly owned subsidiary; therefore, no independent future guidance is provided.

Management Comments

• The transaction was executed pursuant to the Agreement and Plan of Merger dated March 31, 2026.

Industry Context

StockSavvy.ai notes that this acquisition represents a significant consolidation in the biopharmaceutical sector, with Biogen expanding its portfolio through the absorption of Apellis Pharmaceuticals' assets and pipeline.

Comparison to Industry Standards

• The use of CVRs in this acquisition is consistent with recent trends in biotech M&A, where acquirers mitigate risk by tying a portion of the purchase price to clinical or regulatory success.
• The $41.00 cash offer reflects a standard premium-to-market structure typical of pharmaceutical takeovers.

Stakeholder Impact

• Shareholders receive cash consideration for their equity.
• Employees and management face integration into the Biogen corporate structure.
• Creditors and suppliers will transition to dealing with the surviving entity under Biogen ownership.

Next Steps

• Achievement of milestones related to the CVR agreement.
• Finalization of tax withholding and distribution of merger consideration.

Key Dates

Keywords

Apellis Pharmaceuticals, Biogen, Merger, Acquisition, APLS, Contingent Value Rights, Tender Offer